SCHEMBL31360470

SCHEMBL31360470

CN1CCN(c2cnc3c(C#N)cccc3n2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3A P46098 6/20 0.59
▸ HRH4 Q9H3N8 4/20 0.59
▸ MET P08581 5/20 0.52
▸ ALDH1A1 P00352 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ HTR3E A5X5Y0 2/20 0.47
▸ HTR3B O95264 2/20 0.47
▸ HTR3D Q70Z44 2/20 0.47
▸ HTR3C Q8WXA8 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ THPO P40225 1/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ USP2 O75604 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CLK1 P49759 1/20 0.46
▸ KMT2A Q03164 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30492321 0.90 MET (0.62) HTR3AHRH4METALDH1A1KDM4E
SCHEMBL31360500 0.88 CNR2 (0.46) HTR3AHRH4METALDH1A1KDM4E
SCHEMBL30492275 0.77 MET (0.46) HTR3AHRH4METALDH1A1KDM4E
Hydrochloric Acid SCHEMBL31017698 0.76 HCRTR1 (0.43) HTR3AHRH4
SCHEMBL6420262 0.75 NR1H2 (0.40) TSHRKMT2AMAPTHTT
SCHEMBL606857 0.75 HRH4 (1.00) HTR3AHRH4METALDH1A1KDM4E
SCHEMBL30492260 0.74 AR (0.47) HTR3AHRH4METALDH1A1KDM4E
SCHEMBL30492258 0.74 MAP4K4 (0.52) HTR3AHRH4METALDH1A1NPC1
SCHEMBL25193210 0.74 HTT (0.54) METALDH1A1KDM4ENPC1GAA
SCHEMBL30492264 0.74 MET (0.46) HTR3AMETALDH1A1KDM4EHTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746871-A2 METHOD OF ENHANCED ABSORPTION OF QUINOXALINE TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ELIXIRON IMMUNOTHERAPEUTICS INC. (TW) 2026-05-27 — — EP disclosed
WO-2025019622-A2 METHOD OF ENHANCED ABSORPTION OF QUINOXALINE TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ELIXIRON IMMUNOTHERAPEUTICS INC. (TW) 2025-01-23 — — WO disclosed
Send feedback